{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T10:28:03Z","timestamp":1784802483346,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,28]],"date-time":"2014-01-28T00:00:00Z","timestamp":1390867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"}],"content-domain":{"domain":["cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.canlet.2014.01.014","type":"journal-article","created":{"date-parts":[[2014,1,25]],"date-time":"2014-01-25T10:32:12Z","timestamp":1390645932000},"page":"309-317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["mTOR is a promising therapeutical target in a subpopulation of pancreatic adenocarcinoma"],"prefix":"10.1016","volume":"346","author":[{"given":"Wesley K.","family":"Utomo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilvapathy","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Biermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper H.J.","family":"van Eijck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco J.","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maikel P.","family":"Peppelenbosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Braat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2014.01.014_b0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2014.01.014_b0010","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2014.01.014_b0015","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.soc.2009.09.009","article-title":"Randomized clinical trials in pancreatic adenocarcinoma","volume":"19","author":"Rudloff","year":"2010","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"10.1016\/j.canlet.2014.01.014_b0020","series-title":"American Cancer Society. Cancer Facts & Figures 2012","author":"A.C. Society","year":"2012"},{"key":"10.1016\/j.canlet.2014.01.014_b0025","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"U. groupe tumeurs digestives of, P. intergroup, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2014.01.014_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2011.11.034","article-title":"Pancreatic cancer: promise for personalised medicine?","volume":"318","author":"Braat","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2014.01.014_b0035","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1126\/science.1164368","article-title":"Core signaling pathways in human pancreatic cancers revealed by global genomic analyses","volume":"321","author":"Jones","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.canlet.2014.01.014_b0040","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ccr.2012.07.024","article-title":"EGF receptor is required for KRAS-induced pancreatic tumorigenesis","volume":"22","author":"Ardito","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2014.01.014_b0045","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2011.12.042","article-title":"Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia","volume":"142","author":"Kanda","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2014.01.014_b0050","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0002-9440(10)64432-X","article-title":"Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia","volume":"161","author":"van Heek","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2014.01.014_b0055","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4161\/sgtp.2.5.17367","article-title":"Ras, PI3K\/Akt and senescence: paradoxes provide clues for pancreatic cancer therapy","volume":"2","author":"Kennedy","year":"2011","journal-title":"Small GTPases"},{"key":"10.1016\/j.canlet.2014.01.014_b0060","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.drup.2007.11.003","article-title":"Targeting the PI3K\/Akt\/mTOR pathway: effective combinations and clinical considerations","volume":"11","author":"LoPiccolo","year":"2008","journal-title":"Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.canlet.2014.01.014_b0065","doi-asserted-by":"crossref","first-page":"e44146","DOI":"10.1371\/journal.pone.0044146","article-title":"K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo","volume":"7","author":"Hofmann","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.canlet.2014.01.014_b0070","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/sj.bjc.6605819","article-title":"Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer","volume":"103","author":"Garrido-Laguna","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2014.01.014_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2012.01.005","article-title":"MTOR inhibitors in cancer therapy","volume":"319","author":"Zaytseva","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2014.01.014_b0080","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2174\/187152010793498663","article-title":"Updates of mTOR inhibitors","volume":"10","author":"Zhou","year":"2010","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"10.1016\/j.canlet.2014.01.014_b0085","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/1471-2407-10-368","article-title":"Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies","volume":"10","author":"Javle","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2014.01.014_b0090","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1158\/0008-5472.CAN-04-3640","article-title":"Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase\/protein kinase B inhibitors","volume":"65","author":"Takeuchi","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2014.01.014_b0095","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/PAI.0b013e3181de115b","article-title":"The mTOR pathway is frequently activated in pancreatic ductal adenocarcinoma and chronic pancreatitis","volume":"18","author":"Bellizzi","year":"2010","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.canlet.2014.01.014_b0100","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.molmed.2005.06.007","article-title":"An expanding role for mTOR in cancer","volume":"11","author":"Guertin","year":"2005","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.canlet.2014.01.014_b0105","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"Sarbassov","year":"2004","journal-title":"Curr. Biol."},{"key":"10.1016\/j.canlet.2014.01.014_b0110","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/0092-8674(92)90643-Q","article-title":"Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70kd S6 protein kinases","volume":"69","author":"Chung","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2014.01.014_b0115","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2014.01.014_b0120","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.2008.18.9514","article-title":"Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer","volume":"27","author":"Wolpin","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2014.01.014_b0125","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1093\/carcin\/bgs214","article-title":"IL-6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer","volume":"33","author":"Li","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2014.01.014_b0130","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/01.pas.0000149710.01559.fe","article-title":"Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver","volume":"29","author":"Hornick","year":"2005","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.canlet.2014.01.014_b0135","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1200\/JCO.2008.21.5988","article-title":"Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway","volume":"28","author":"Missiaglia","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2014.01.014_b0140","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ceb.2009.10.007","article-title":"MTOR and cancer: many loops in one pathway","volume":"22","author":"Efeyan","year":"2010","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.canlet.2014.01.014_b0145","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1158\/0008-5472.CAN-09-0299","article-title":"Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin","volume":"69","author":"Yu","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2014.01.014_b0150","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1042\/BST0390451","article-title":"Blocking the mTOR pathway: a drug discovery perspective","volume":"39","author":"Garcia-Echeverria","year":"2011","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.canlet.2014.01.014_b0155","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ccr.2012.10.023","article-title":"JAK2\/STAT5 inhibition circumvents resistance to PI3K\/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer","volume":"22","author":"Britschgi","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2014.01.014_b0160","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF02788442","article-title":"Homogeneity and heterogeneity in pancreas cancer: presence of predominant and minor morphological types and implications","volume":"1","author":"Fitzgerald","year":"1986","journal-title":"Int. J. Pancreatol."},{"key":"10.1016\/j.canlet.2014.01.014_b0165","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ccr.2012.10.025","article-title":"Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma","volume":"22","author":"Kopp","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2014.01.014_b0170","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/ijms14010273","article-title":"Antitumor effects of rapamycin in pancreatic cancer cells by inducing apoptosis and autophagy","volume":"14","author":"Dai","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2014.01.014_b0175","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/sj.onc.1209992","article-title":"Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells","volume":"26","author":"Iwamaru","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2014.01.014_b0180","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1101\/gad.2016111","article-title":"Pancreatic cancers require autophagy for tumor growth","volume":"25","author":"Yang","year":"2011","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2014.01.014_b0185","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1038\/onc.2010.630","article-title":"The long and winding road to rational treatment of cancer associated with LKB1\/AMPK\/TSC\/mTORC1 signaling","volume":"30","author":"van Veelen","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2014.01.014_b0190","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0002-9440(10)65314-X","article-title":"LKB1 somatic mutations in sporadic tumors","volume":"154","author":"Avizienyte","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2014.01.014_b0195","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0002-9440(10)65440-5","article-title":"Germline and somatic mutations of the STK11\/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers","volume":"154","author":"Su","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2014.01.014_b0200","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1200\/JCO.2010.32.7825","article-title":"MTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome","volume":"29","author":"Klumpen","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2014.01.014_b0205","doi-asserted-by":"crossref","first-page":"8571","DOI":"10.1038\/sj.onc.1207902","article-title":"The PI 3-kinase\/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells","volume":"23","author":"Asano","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2014.01.014_b0210","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"T.T.S.G. Rad001 in advanced neuroendocrine tumors, everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2014.01.014_b0215","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2014.01.014_b0220","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2014.01.014_b0225","first-page":"4573","article-title":"Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells","volume":"60","author":"von Wichert","year":"2000","journal-title":"Cancer Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383514000408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383514000408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T13:30:08Z","timestamp":1648128608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383514000408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0304383514000408"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2014.01.014","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mTOR is a promising therapeutical target in a subpopulation of pancreatic adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2014.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}